296 related articles for article (PubMed ID: 32127391)
1. Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer.
Chen B; Alvarado DM; Iticovici M; Kau NS; Park H; Parikh PJ; Thotala D; Ciorba MA
Cancer Immunol Res; 2020 Apr; 8(4):451-464. PubMed ID: 32127391
[TBL] [Abstract][Full Text] [Related]
2. IDO1 and Kynurenine Pathway Metabolites Activate PI3K-Akt Signaling in the Neoplastic Colon Epithelium to Promote Cancer Cell Proliferation and Inhibit Apoptosis.
Bishnupuri KS; Alvarado DM; Khouri AN; Shabsovich M; Chen B; Dieckgraefe BK; Ciorba MA
Cancer Res; 2019 Mar; 79(6):1138-1150. PubMed ID: 30679179
[TBL] [Abstract][Full Text] [Related]
3. IDO1 Inhibition Overcomes Radiation-Induced "Rebound Immune Suppression" by Reducing Numbers of IDO1-Expressing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Li A; Barsoumian HB; Schoenhals JE; Caetano MS; Wang X; Menon H; Valdecanas DR; Niknam S; Younes AI; Cortez MA; Welsh JW
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):903-912. PubMed ID: 30905636
[TBL] [Abstract][Full Text] [Related]
4. IDO1 metabolites activate β-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice.
Thaker AI; Rao MS; Bishnupuri KS; Kerr TA; Foster L; Marinshaw JM; Newberry RD; Stenson WF; Ciorba MA
Gastroenterology; 2013 Aug; 145(2):416-25.e1-4. PubMed ID: 23669411
[TBL] [Abstract][Full Text] [Related]
5. Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model.
Poncelet L; Ait-Belkacem R; Marillier R; Gomes B; Stauber J
J Pharm Biomed Anal; 2019 Jun; 170():220-227. PubMed ID: 30933897
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-Dioxygenase 1 Inhibitor-Loaded Nanosheets Enhance CAR-T Cell Function in Esophageal Squamous Cell Carcinoma.
Shao J; Hou L; Liu J; Liu Y; Ning J; Zhao Q; Zhang Y
Front Immunol; 2021; 12():661357. PubMed ID: 33828565
[TBL] [Abstract][Full Text] [Related]
8. Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth.
Phan T; Nguyen VH; D'Alincourt MS; Manuel ER; Kaltcheva T; Tsai W; Blazar BR; Diamond DJ; Melstrom LG
Cancer Gene Ther; 2020 Apr; 27(3-4):235-245. PubMed ID: 30824815
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the BET family reduces its new target gene IDO1 expression and the production of L-kynurenine.
Tian CQ; Chen L; Chen HD; Huan XJ; Hu JP; Shen JK; Xiong B; Wang YQ; Miao ZH
Cell Death Dis; 2019 Jul; 10(8):557. PubMed ID: 31324754
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies.
Shi JG; Bowman KJ; Chen X; Maleski J; Leopold L; Yeleswaram S
J Clin Pharmacol; 2017 Jun; 57(6):720-729. PubMed ID: 27990653
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors.
Song X; Sun P; Wang J; Guo W; Wang Y; Meng LH; Liu H
Eur J Med Chem; 2020 Mar; 189():112059. PubMed ID: 31981851
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis and Biological Evaluation of Novel 1,2,5-Oxadiazol-3- Carboximidamide Derivatives as Indoleamine 2, 3-Dioxygenase 1 (IDO1) Inhibitors.
Xia Z; Nan Y; Liu C; Lin G; Gu K; Chen C; Zhao W; Ju D; Dong X
Anticancer Agents Med Chem; 2020; 20(13):1592-1603. PubMed ID: 32496990
[TBL] [Abstract][Full Text] [Related]
13. The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.
Jochems C; Fantini M; Fernando RI; Kwilas AR; Donahue RN; Lepone LM; Grenga I; Kim YS; Brechbiel MW; Gulley JL; Madan RA; Heery CR; Hodge JW; Newton R; Schlom J; Tsang KY
Oncotarget; 2016 Jun; 7(25):37762-37772. PubMed ID: 27192116
[TBL] [Abstract][Full Text] [Related]
14. IDO Targeting in Sarcoma: Biological and Clinical Implications.
Nafia I; Toulmonde M; Bortolotto D; Chaibi A; Bodet D; Rey C; Velasco V; Larmonier CB; Cerf L; Adam J; Le Loarer F; Savina A; Bessede A; Italiano A
Front Immunol; 2020; 11():274. PubMed ID: 32194552
[TBL] [Abstract][Full Text] [Related]
15. Regulation of kynurenine biosynthesis during influenza virus infection.
Gaelings L; Söderholm S; Bugai A; Fu Y; Nandania J; Schepens B; Lorey MB; Tynell J; Vande Ginste L; Le Goffic R; Miller MS; Kuisma M; Marjomäki V; De Brabander J; Matikainen S; Nyman TA; Bamford DH; Saelens X; Julkunen I; Paavilainen H; Hukkanen V; Velagapudi V; Kainov DE
FEBS J; 2017 Jan; 284(2):222-236. PubMed ID: 27860276
[TBL] [Abstract][Full Text] [Related]
16. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.
Beatty GL; O'Dwyer PJ; Clark J; Shi JG; Bowman KJ; Scherle PA; Newton RC; Schaub R; Maleski J; Leopold L; Gajewski TF
Clin Cancer Res; 2017 Jul; 23(13):3269-3276. PubMed ID: 28053021
[No Abstract] [Full Text] [Related]
17. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of radiation therapy by indoleamine 2,3 dioxygenase 1 inhibition through multimodal mechanisms.
Nozawa H; Taira T; Sonoda H; Sasaki K; Murono K; Emoto S; Yokoyama Y; Nagai Y; Abe S; Ishihara S
BMC Cancer; 2023 Jan; 23(1):62. PubMed ID: 36653774
[TBL] [Abstract][Full Text] [Related]
19. Blockade of IDO-Kynurenine-AhR Axis Ameliorated Colitis-Associated Colon Cancer via Inhibiting Immune Tolerance.
Zhang X; Liu X; Zhou W; Du Q; Yang M; Ding Y; Hu R
Cell Mol Gastroenterol Hepatol; 2021; 12(4):1179-1199. PubMed ID: 34087454
[TBL] [Abstract][Full Text] [Related]
20. A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis.
Xiang Z; Li J; Song S; Wang J; Cai W; Hu W; Ji J; Zhu Z; Zang L; Yan R; Yu Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):314. PubMed ID: 31315643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
